Mutational landscape and predictors of survival in head and neck mucosal melanoma

Lehrich, Brandon M.; Abiri, Arash; Nguyen, Theodore V.; Bitner, Benjamin F.; Tong, Charles C. L.; Kuan, Edward C.

doi:10.1002/alr.23267

Cited by 2 publications

(1 citation statement)

References 13 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study by Lehrich et al discusses the mutational landscape in all HNMM and provides evidence that HNMM patients with a proto-oncogene receptor tyrosine kinase mutation had improved OS, highlighting the potential impact of targeted therapy in treating HNMMs including SNMMs. 79 Moreover, Amit et al report that only around 40% of SNMM patients have detectable genetic mutations suggesting that the genetic markers used for cutaneous melanoma may not have the same utility in SNMM and that new SNMM-specific mutations may lead to better target therapy. 22 Thus, it is evident that the mutations in SNMM are different than the mutations seen in cutaneous melanoma.…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

Tang,

Taori,

Dang

et al. 2024

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this work is to comprehensively review and synthesize the literature related to sinonasal mucosal melanoma (SNMM) treatment with immunotherapy, including potentially targetable genetic mutations, survival outcomes, and adverse events.Data SourcesEmbase, Cochrane, Scopus, and Web of Science.Review MethodsThe study protocol was designed according to Preferred Reporting Items for Systematic Reviews and Meta‐analysis statement. Databases were searched from inception through May 23, 2023.ResultsA total of 42 studies met inclusion criteria. Twenty‐four of the included studies reported genetic mutations for a combined 787 patients with SNMM. 8.1% (95% confidence interval, CI: 7.6‐8.6), 18.9% (95% CI: 18.1‐19.8), and 8.5% (95% CI: 8.1‐9.0) of reported patients were positive for BRAF, NRAS, and KIT mutations, respectively. The presence of brisk tumor‐infiltrating lymphocytes was associated with improved recurrence‐free survival and overall survival (OS). Six studies reported a combined 5‐year OS after adjuvant immunotherapy treatment of 42.6% (95% CI: 39.4‐45.8). Thirteen studies encompassing 117 patients reported adjuvant or salvage immune checkpoint inhibitor (ICI) immunotherapy response rates: 40.2% (95% CI: 36.8‐43.6) had a positive response (tumor volume reduction or resolution). Eleven studies reported direct comparisons between SNMM patients treated with or without immunotherapy; the majority (7/11) reported survival benefit for their entire cohort or select subgroups of SNMM patients. With the transition to modern ICIs, there is a stronger trend toward survival improvement with adjuvant ICI. Tumors with Ki67 <40% may respond better to ICI's.ConclusionICI therapy can be an effective in select SNMM patients, especially those with advanced/metastatic disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

Tang,

Taori,

Dang

et al. 2024

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

show abstract

Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database

Lehrich,

Tong,

Hsu

et al. 2024

Childs Nerv Syst

View full text Add to dashboard Cite

Mutational landscape and predictors of survival in head and neck mucosal melanoma

Abstract: Key Points Head and neck mucosal melanomas have a diverse mutational landscape with low mutational burden. A molecular subset (∼13%) has ROS1 mutations, which is an actionable driver mutation. ROS1‐mutated patients have improved overall survival likely due to high mutational burden.

Cited by 2 publications

References 13 publications

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database

Contact Info

Product

Resources

About